Exhibitor

 AcroCyte Therapeutics, Inc.

TaiwanInnoVEX 2026  S0311a

Corporation

Healthcare & Biotech

Pavilion: SMESA Theme Pavilion

Online Matchmaking Funding Stage: pre A Round Founding Year: 2020
Looking for
R³CE® 3D Cell Culture Plate's photo

R³CE® 3D Cell Culture Plate

The AcroCyte R³CE® 3D Cell Culture Plate is a globally unique scaffold-free platform engineered for the efficient expansion of extremely rare cells, including circulating tumor cells (CTCs), biopsy-derived cells, and stem cells. Its optimized 3D microenvironment enhances natural cell–cell and cell–matrix interactions, closely replicating in vivo physiological conditions while maintaining cellular heterogeneity and functional integrity.

R³CE® Organoid Culture Medium's photo

R³CE® Organoid Culture Medium

The AcroCyte R3CE® Organoids Medium is a precisely formulated, application‑driven solution for robust and reproducible generation of patient‑derived organoids from diverse clinical specimens, including surgical tissues, needle biopsies, and liquid biopsies. Fully compatible with the R3CE® scaffold‑free platform, it supports efficient establishment, expansion, and long‑term maintenance of organoids while preserving native architecture, cellular heterogeneity, and functional characteristics. The medium enables organoid formation within as little as two weeks across multiple tissue types, supporting downstream applications such as drug screening and multi‑omics analysis.

's photo

Company Description

AcroCyte is redefining precision medicine through its breakthrough R3CE® (Rapid, Reproducible, Rare Cell 3D Expansion) technology.
R3CE® is a next-generation 3D cell culture platform that enables the direct isolation and expansion of circulating tumor cells (CTCs) from blood, generating patient-specific 3D tumor models.
The platform has demonstrated strong feasibility in both clinical and real-world settings, enabling the expansion of single cells into clinically relevant 3D spheroids without relying on conventional cell lines or animal models.
Through its Onco-REAL™ clinical service, AcroCyte delivers personalized and predictive solutions for cancer treatment.